{"id":"clinically-prescribed-direct-acting-antiviral","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Direct-acting antivirals (DAAs) target specific viral proteins such as proteases, polymerases, or other essential enzymes needed for the viral life cycle. By binding to and inhibiting these molecular targets, DAAs block viral replication at a specific step, reducing viral load. This class has been most extensively developed and clinically validated for hepatitis C virus (HCV) and more recently for SARS-CoV-2 and other viral infections.","oneSentence":"Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from reproducing within host cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:43:39.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral infection (specific virus and indication not specified in provided information)"}]},"trialDetails":[{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT03208244","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-09","conditions":"End Stage Heart Disease, Hepatitis C","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":107,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DAA treatment"],"phase":"marketed","status":"active","brandName":"Clinically prescribed direct acting antiviral","genericName":"Clinically prescribed direct acting antiviral","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from reproducing within host cells. Used for Viral infection (specific virus and indication not specified in provided information).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}